Similar articles

• [Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer--a multi-institutional update].

  Graefen M. Graefen M. Aktuelle Urol. 2004 Sep;35(5):377-8. doi: 10.1055/s-2004-834369. Aktuelle Urol. 2004. PMID: 15384003 German. No abstract available.
• Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.

  Southwick PC, Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, Walsh PC, Scardino PT, Lange PH, Gasior GH, Parson RE, Loveland KG. Southwick PC, et al. J Urol. 1999 Oct;162(4):1346-51. J Urol. 1999. PMID: 10492194 Clinical Trial.
• Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.

  Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG. Lehrer S, et al. Br J Cancer. 2002 Sep 23;87(7):726-8. doi: 10.1038/sj.bjc.6600526. Br J Cancer. 2002. PMID: 12232754 Free PMC article.
• The use of percent free prostate specific antigen for staging clinically localized prostate cancer.

  Pannek J, Rittenhouse HG, Chan DW, Epstein JI, Walsh PC, Partin AW. Pannek J, et al. J Urol. 1998 Apr;159(4):1238-42. J Urol. 1998. PMID: 9507844 Review.
• Prognostic markers in clinically localized prostate cancer.

  Pettaway CA. Pettaway CA. Tech Urol. 1998 Mar;4(1):35-42. Tech Urol. 1998. PMID: 9568775 Review.